IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012
Summary
Global Markets Direct's pharmaceuticals report, 'IMPAX Laboratories, Inc. - Product Pipeline Review - 2012' provides data on the IMPAX Laboratories, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct's proprietary databases, IMPAX Laboratories, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from IMPAX Laboratories, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- IMPAX Laboratories, Inc. - Brief IMPAX Laboratories, Inc. overview including business description, key information and facts, and its locations and subsidiaries.- Review of current pipeline of IMPAX Laboratories, Inc. human therapeutic division.- Overview of pipeline therapeutics across various therapy areas.- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.- Product profiles for late stage and clinical stage products of IMPAX Laboratories, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the IMPAX Laboratories, Inc.'s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate IMPAX Laboratories, Inc.'s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of IMPAX Laboratories, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the IMPAX Laboratories, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with IMPAX Laboratories, Inc.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of IMPAX Laboratories, Inc. and identify potential opportunities in those areas.
IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012
1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012
Published on August 2012
Report Summary
IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012
Summary
Global Markets Direct's pharmaceuticals report, 'IMPAX Laboratories, Inc. - Product Pipeline Review - 2012' provides data on the
IMPAX Laboratories, Inc.'s research and development focus. The report includes information on current developmental pipeline,
complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, IMPAX Laboratories, Inc.'s
corporate website, SEC filings, investor presentations and featured press releases, both from IMPAX Laboratories, Inc. and
industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- IMPAX Laboratories, Inc. - Brief IMPAX Laboratories, Inc. overview including business description, key information and facts, and its
locations and subsidiaries.
- Review of current pipeline of IMPAX Laboratories, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of IMPAX Laboratories, Inc. with complete description of the product's
developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the IMPAX Laboratories, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate IMPAX Laboratories, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of IMPAX Laboratories, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the IMPAX Laboratories, Inc.'s R&D portfolio and develop key strategic
initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with IMPAX Laboratories, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of IMPAX Laboratories, Inc. and identify potential opportunities in those areas.
IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/7
2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Table of Content
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
IMPAX Laboratories, Inc. Snapshot 6
IMPAX Laboratories, Inc. Overview 6
Key Information 6
Key Facts 6
IMPAX Laboratories, Inc. ' Research and Development Overview 7
Key Therapeutic Areas 7
IMPAX Laboratories, Inc. ' Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products ' Monotherapy 10
IMPAX Laboratories, Inc. ' Pipeline Products Glance 11
IMPAX Laboratories, Inc. ' Late Stage Pipeline 11
Registration Filed Products/Combination Treatment Modalities 11
IMPAX Laboratories, Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
IMPAX Laboratories, Inc. ' Drug Profiles 13
IPX056 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
IPX066 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
IPX159 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
IMPAX Laboratories, Inc. ' Pipeline Products by Route of Administration 18
IMPAX Laboratories, Inc. ' Pipeline Products By Mechanism of Action 19
IMPAX Laboratories, Inc. ' Recent Pipeline Updates 20
IMPAX Laboratories, Inc. - Dormant Projects 23
IMPAX Laboratories, Inc. ' Company Statement 24
IMPAX Laboratories, Inc. ' Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
IMPAX Laboratories, Inc., Recent Developments 27
IMPAX Laboratories, Inc.- Press Release 27
Apr 18, 2012: Impax To Presents Data From ASCEND-PD Phase III Study Of IPX066 At American Academy Of Neurology
Conference 27
Feb 23, 2012: FDA Accepts NDA Filing For IPX066 For Treatment Of Idiopathic Parkinson's Disease 27
IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 2/7
3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Dec 02, 2009: Impax Laboratories Acquires Rights to Abbreviated New Drug Applications 28
Oct 27, 2009: Impax Pharmaceuticals Commences Phase III trial Of IPX066 Drug In PD patients 28
Oct 07, 2009: Impax Laboratories Settles Pending Litigation for FLOMAX 29
Oct 05, 2009: Impax Laboratories Receives Tentative FDA Approval for Generic FLOMAX 0.4mg Capsules 29
Oct 01, 2009: Impax Starts Shipment Of Generic Adderall XR Capsules 29
Sep 23, 2009: Impax Pharmaceuticals Presents Positive Results Of Phase II Trial Of IPX066 30
Sep 21, 2009: Impax Pharmaceuticals Reports Positive Results of Phase II Trial of IPX066, a Novel Formulation of
Carbidopa-Levodopa for Parkinson's Disease 30
Aug 05, 2009: Impax Laboratories Receives Final FDA Approval for Generic Depakote Extended-Release 500mg Tablets 31
Jun 08, 2009: Impax Pharmaceuticals Presents Phase II Data at 13th International Congress Of Parkinson's Disease And Movement
Disorders 31
May 19, 2009: Impax Receives FDA Approval for Generic Precose Tablets, 25 mg, 50 mg and 100 mg 32
May 06, 2009: Impax Receives Final FDA Approval for Generic Depakote Extended-Release 250mg Tablets 32
Apr 22, 2009: Impax Pharmaceuticals Presents Positive Achievements On Its Two Leading Brand Product Candidates Including
IPX066 33
Apr 20, 2009: Impax Pharmaceuticals Commences A Phase III Trial Of IPX066 33
Apr 20, 2009: Impax Pharmaceuticals Reports Positive Achievements On Its Leading Brand Product Candidate IPX056 33
Mar 20, 2009: Impax Confirms Patent Lawsuit Relating to Doryx Tablets 150 mg 34
Mar 17, 2009: Impax Confirms ANDA Filing For Doryx Tablets 150mg 34
Jan 26, 2009: IMPAX Receives Final FDA Approval For Omeprazole 40 Mg Capsules 34
Financial Deals Landscape 35
IMPAX Laboratories, Inc., Deals Summary 35
IMPAX Laboratories, Inc., Pharmaceuticals & Healthcare, Deal Details 37
Asset Transactions 37
Impax Labs Acquires Abbreviated New Drug Applications Rights From Watson Pharma 37
Impax Labs Acquires ANDA Rights Of Dronabinol From Cobalt Labs 39
Partnerships 40
Impax Labs Enters Into Development And Distribution Agreement With Tolmar 40
IMPAX Lab Enters Into Co-Development Agreement With TOLMAR 42
IMPAX Labs Enters Into Co-Marketing Agreement With Banner Pharmacaps 43
Impax Labs Enters Into Co-Development Agreement With Perrigo 44
IGI Labs Enters Into Co-Development Agreement With IMPAX Labs 45
IMPAX Labs Amends Co-Promotion Agreement With Wyeth 46
IMPAX Labs Enters Into Co-Promotion Agreement With Wyeth 47
Medicis Pharma Enters Into An Agreement With IMPAX Labs 48
Intec Pharma Enters Into Co-Development Agreement With IMPAX Labs 49
Impax Labs Enters Into Co-Promotion Agreement With Shire For Carbatrol 50
IMPAX Labs Enters Into Co-Marketing Agreement With Shire For Adderall XR 51
Licensing Agreements 52
Impax Pharma Enters Into Licensing Agreement With AstraZeneca For Zomig 52
GlaxoSmithKline Enters Into Licensing Agreement With Impax Pharma For IPX066 53
IMPAX Labs Enters Into Licensing Agreement With Endo Pharma 55
Endo Pharma And Penwest Pharma Enter Into Licensing Agreement With Impax Labs 56
Medicis Pharma Enters Into Licensing Agreement With IMPAX Labs 57
Wyeth Enters Into Agreement With IMPAX 58
Impax Labs Enters Into Licensing Agreement With Wyeth 59
Impax Labs Enters Into Licensing Agreement With Purdue Pharma 60
Impax Labs Enters Into Licensing Agreement With DAVA Pharma 61
IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 3/7
4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 6
List of Tables
IMPAX Laboratories, Inc., Key Information 6
IMPAX Laboratories, Inc., Key Facts 6
IMPAX Laboratories, Inc. ' Pipeline by Indication, 2012 8
IMPAX Laboratories, Inc. ' Pipeline by Stage of Development, 2012 9
IMPAX Laboratories, Inc. ' Monotherapy Products in Pipeline, 2012 10
IMPAX Laboratories, Inc. ' Filed, 2012 11
IMPAX Laboratories, Inc. ' Phase II, 2012 12
IMPAX Laboratories, Inc. ' Pipeline By Route of Administration, 2012 18
IMPAX Laboratories, Inc. ' Pipeline Products By Mechanism of Action, 2012 19
IMPAX Laboratories, Inc. ' Recent Pipeline Updates, 2012 20
IMPAX Laboratories, Inc. - Dormant Developmental Projects,2012 23
IMPAX Laboratories, Inc., Other Locations 26
IMPAX Laboratories, Inc., Subsidiaries 26
IMPAX Laboratories, Inc., Deals Summary 35
Impax Labs Acquires Abbreviated New Drug Applications Rights From Watson Pharma 37
Impax Labs Acquires ANDA Rights Of Dronabinol From Cobalt Labs 39
Impax Labs Enters Into Development And Distribution Agreement With Tolmar 40
IMPAX Lab Enters Into Co-Development Agreement With TOLMAR 42
IMPAX Labs Enters Into Co-Marketing Agreement With Banner Pharmacaps 43
Impax Labs Enters Into Co-Development Agreement With Perrigo 44
IGI Labs Enters Into Co-Development Agreement With IMPAX Labs 45
IMPAX Labs Amends Co-Promotion Agreement With Wyeth 46
IMPAX Labs Enters Into Co-Promotion Agreement With Wyeth 47
Medicis Pharma Enters Into An Agreement With IMPAX Labs 48
Intec Pharma Enters Into Co-Development Agreement With IMPAX Labs 49
Impax Labs Enters Into Co-Promotion Agreement With Shire For Carbatrol 50
IMPAX Labs Enters Into Co-Marketing Agreement With Shire For Adderall XR 51
Impax Pharma Enters Into Licensing Agreement With AstraZeneca For Zomig 52
GlaxoSmithKline Enters Into Licensing Agreement With Impax Pharma For IPX066 53
IMPAX Labs Enters Into Licensing Agreement With Endo Pharma 55
Endo Pharma And Penwest Pharma Enter Into Licensing Agreement With Impax Labs 56
Medicis Pharma Enters Into Licensing Agreement With IMPAX Labs 57
Wyeth Enters Into Agreement With IMPAX 58
Impax Labs Enters Into Licensing Agreement With Wyeth 59
Impax Labs Enters Into Licensing Agreement With Purdue Pharma 60
Impax Labs Enters Into Licensing Agreement With DAVA Pharma 61
IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 4/7
5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
List of Figures
IMPAX Laboratories, Inc. ' Pipeline by Indication, 2012 8
IMPAX Laboratories, Inc. ' Pipeline by Stage of Development, 2012 9
IMPAX Laboratories, Inc. ' Monotherapy Products in Pipeline, 2012 10
IMPAX Laboratories, Inc. - Pipeline Products By Mechanism of Action, 2012 19
IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 5/7
6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 1 500.00 Quantity: _____
Site License--USD 3 000.00 Quantity: _____
Corporate License--USD 4 500.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 6/7
7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 7/7